As a striking example of tissue specific effects, although loss of function for PTEN, a FTExT gene, is a well-known indicator of tumor aggressiveness [34], this carcinoma-associated tumor suppressor gene appears to be overexpressed in myeloma patients with poor clinical outcome [33]. This evidence concerns the gene PTEN and carcinoma.